Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms
- PMID: 12920066
- PMCID: PMC1735560
- DOI: 10.1136/jmg.40.8.575
Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms
Abstract
Methods: The 22q13 deletion syndrome (MIM 606232) is characterised by moderate to profound mental retardation, delay/absence of expressive speech, hypotonia, normal to accelerated growth, and mild dysmorphic features. We have determined the deletion size and parent of origin in 56 patients with this syndrome.
Results: Similar to other terminal deletion syndromes, there was an overabundance of paternal deletions. The deletions vary widely in size, from 130 kb to over 9 Mb; however all 45 cases that could be specifically tested for the terminal region at the site of SHANK3 were deleted for this gene. The molecular structure of SHANK3 was further characterised. Comparison of clinical features to deletion size showed few correlations. Some measures of developmental assessment did correlate to deletion size; however, all patients showed some degree of mental retardation and severe delay or absence of expressive speech, regardless of deletion size.
Conclusion: Our analysis therefore supports haploinsufficiency of the gene SHANK3, which codes for a structural protein of the postsynaptic density, as a major causative factor in the neurological symptoms of 22q13 deletion syndrome.
Similar articles
-
Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome.Am J Hum Genet. 2001 Aug;69(2):261-8. doi: 10.1086/321293. Epub 2001 Jun 18. Am J Hum Genet. 2001. PMID: 11431708 Free PMC article.
-
Interstitial 22q13 deletions: genes other than SHANK3 have major effects on cognitive and language development.Eur J Hum Genet. 2008 Nov;16(11):1301-10. doi: 10.1038/ejhg.2008.107. Epub 2008 Jun 4. Eur J Hum Genet. 2008. PMID: 18523453
-
22q13.3 deletion syndrome: clinical and molecular analysis using array CGH.Am J Med Genet A. 2010 Mar;152A(3):573-81. doi: 10.1002/ajmg.a.33253. Am J Med Genet A. 2010. PMID: 20186804 Free PMC article.
-
22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay.Am J Med Genet C Semin Med Genet. 2007 Nov 15;145C(4):393-8. doi: 10.1002/ajmg.c.30155. Am J Med Genet C Semin Med Genet. 2007. PMID: 17926345 Review.
-
A previously unrecognized 22q13.2 microdeletion syndrome that encompasses TCF20 and TNFRSF13C.Am J Med Genet A. 2018 Dec;176(12):2791-2797. doi: 10.1002/ajmg.a.40492. Epub 2018 Sep 14. Am J Med Genet A. 2018. PMID: 30216695 Review.
Cited by
-
Haploinsufficiency of Shank3 increases the orientation selectivity of V1 neurons.Sci Rep. 2022 Dec 23;12(1):22230. doi: 10.1038/s41598-022-26402-9. Sci Rep. 2022. PMID: 36564435 Free PMC article.
-
Spinophilin Limits Metabotropic Glutamate Receptor 5 Scaffolding to the Postsynaptic Density and Cell Type Specifically Mediates Excessive Grooming.Biol Psychiatry. 2023 Jun 1;93(11):976-988. doi: 10.1016/j.biopsych.2022.12.008. Epub 2022 Dec 13. Biol Psychiatry. 2023. PMID: 36822932 Free PMC article.
-
Descriptive Analysis of Adaptive Behavior in Phelan-McDermid Syndrome and Autism Spectrum Disorder.Front Neurosci. 2022 Jul 4;16:893003. doi: 10.3389/fnins.2022.893003. eCollection 2022. Front Neurosci. 2022. PMID: 35864987 Free PMC article.
-
Variability in Phelan-McDermid Syndrome in a Cohort of 210 Individuals.Front Genet. 2022 Apr 12;13:652454. doi: 10.3389/fgene.2022.652454. eCollection 2022. Front Genet. 2022. PMID: 35495150 Free PMC article.
-
CRISPR/Cas9-mediated disruption of SHANK3 in monkey leads to drug-treatable autism-like symptoms.Hum Mol Genet. 2019 Feb 15;28(4):561-571. doi: 10.1093/hmg/ddy367. Hum Mol Genet. 2019. PMID: 30329048 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous